Rubius Therapeutics Inc. sell nvestor
Start price
14.12.20
/
50%
€7.90
Target price
14.12.21
€2.00
Performance (%)
158.23%
End price
26.06.21
€20.40
Summary
This prediction ended on 26.06.21 with a price of €20.40. The price for Rubius Therapeutics Inc. massively increased, which is bad news for the SELL prediction by nvestor. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Rubius Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
According to nvestor what are the pros and cons of Rubius Therapeutics Inc. for the foreseeable future?
Pros
Cons
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
overvalued
Junk rating
Very little Investments for future growth
Very low/no dividend yield expected
very negative Cash Flow expected
High risks in the balance sheet
High challenges to pay loans and raise capital
ROE lower than 5% per year
Deficits in Management
Very bad culture
No Innovation
No uniques
Growths much slower than the competition
Sustainability is not important
Dependend from few customers or products
High risks for its business
Mainly gamblers invest here
Nicheplayer
Very high cyclical dependencies
Outdated or very high risk business model
Comments by nvestor for this prediction
In the thread Rubius Therapeutics Inc. diskutieren
In the thread Trading Rubius Therapeutics Inc.
Stopped prediction by nvestor for Rubius Therapeutics Inc.
Rubius Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.00
09.04.22
09.04.22
€1.00
09.04.23
09.04.23
-47.00%
16.04.22
16.04.22
Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
Decining EBIT margin than peer group
